Editorial
Long Term Effects of Endoscopic Sclerotherapy on the Oesophagus
Peeyush P Sharma* and Dave Krishan Sharma
Department of Surgery, British Institute of Aesthetic Medicine, UK
*Corresponding author: Peeyush P. Sharma, Department of Surgery, British Institute of Aesthetic Medicine, Cambridgeshire, UK
Published: 01 Nov, 2018
Cite this article as: Sharma PP, Sharma DK. Long Term
Effects of Endoscopic Sclerotherapy
on the Oesophagus. Clin Surg. 2018;
3: 2194.
Editorial
Portal hypertension and its secondary effects significantly contribute to the morbidity and
mortality in patients with advanced liver disease [1]. Due to a progressive rise in portal pressure,
peri-esophageal portal- systemic circulatory pathways open up as a means to establish collateral
circulation, which is essentially an attempt by the body to “shunt” portal blood which is at a higher
pressure, into the systemic circulation in the region, which is at a lower pressure. This collateral
portal-systemic circulation is represented by distal esophageal varices [2]. The oesophageal varices
can be rapidly fatal from their ability to bleed. Over the years several modalities have been used to
control the bleeding by decompression of the portal venous system by mesocaval or other shunts or
by variceal sclerotherapy or ligation etc. Transjugular Intrahepatic Portal Systemic Shunting (TIPS)
has been used but this treatment is plagued by shunt dysfunction arising in up to 50% of patients
when bare metal stents are used and somewhat lower when covered stent graft is used [3]. However,
use of small calibre TIPS may offer clinical benefits while at the same time delay the development of
encephalopathy. Liver transplantation has also been used as a treatment option in selected patients. In
a clinical situation however, where one is confronted with a severely ill patient who is bleeding from
oesophageal varices and is unsuitable for anaesthetic and surgical intervention, endoscopic variceal
ligation and Endoscopic Sclerotherapy (EST) can save the patient’s life. Currently, endoscopic
sclerotherapy should be reserved for high risk patients as this saves lives. There is a huge clinical
experience in the use of EST in the treatment of oesophageal varices. Endoscopic sclerotherapy
however has by far been the mainstay of management of these patients for many decades. Many of
us, who have seen these patients for years, have also noticed the severe aftereffects of EST. Although
several groups have earlier conducted manometric studies on the oesophagus following EST, our
group conducted one of the first studies attempting to correlate histologic changes with manometric
studies in patients who had been treated with EST earlier [4]. We shall review the current status of
our knowledge in developing an understanding of the correlation between histologic changes and
manometric abnormalities following EST.
Portal-systemic collaterals are predominantly intramucosal and in the submucosa of the distal
oesophagus, gastroesophageal junction and even the gastric fundus [5,6]. Once the portal venous
pressure surpasses 10 mmHg, predisposition to development of portal-systemic collaterals (varices),
is high. However, vulnerability of varices to cause life threatening bleeding invariably exists at 12
mmHg and over. Variceal bleeding however is dependent upon location, size etc. Bleeding from
variceal rupture combined with ascites, jaundice, deteriorating hepatic metabolic function and
encephalopathy contribute to the significant morbidity and mortality of these very ill patients.
Management of acute variceal bleeding should be prioritized and if a risk group has been
identified then prevention of bleeding by for example adjuvant therapy with Non-Selective Beta
Blockers (NSBB), renin- angiotensin system inhibitors, statins etc. should be considered [8-10]. In
acute bleeding however, small calibre TIPS can be useful as noted earlier, however its availability
may be the limiting factor. The “turning off” of the bleeders endoscopically by ligation and/or
sclerotherapy can save lives and helps buy time for more substantive measures like meso-caval
shunting or liver transplantation etc. in the most severe cases. Often on entering the oesophagus
with a forward looking scope, one can’t see anything due to clots and altered and fresh blood.
Meticulous evacuation of clots and other material is critical in establishing a clear enough view to
endoscopically identify and sclerose the bleeding varices. It is essential that this is done by surgeons
or in the presence of surgeons in order to develop an understanding of the clinical situation and
reduce the transit to an operative option should all else fail. The use of NSBB in the prophylactic
treatment of these “bleeders” to prevent rebleeds is beyond the scope of this paper. The patients
who have been treated successfully with EST and go on to have several sessions and finally go into
remission or a compensated state, report the symptoms characteristic
of the post- EST period.
In our original work published earlier, it was found that the
severity of manometric and histologic changes could be correlated to
the severity of esophageal dysmotility but was unrelated to the total
amount of sclerosant used in any patient [4]. The severity of histologic
and manometric changes was related to the number of sclerotherapy
sessions that the patients had had. In fact, it would appear that the
manometric changes after EST are not caused by the sclerosant itself.
This is supported by the fact that the dysmotility and the symptoms
attributable to it, do not appear in the immediate post-EST period.
These appear several months after the repeated EST and in patients
who have become asymptomatic from their original condition,
whether by EST alone or some other definitive treatment. It is
therefore reasonable to hypothesise that the chronic inflammatory
changes seen in the distal oesophagus after repeated EST are the
trigger for the dysmotility and may well lend themselves to treatment
once we understand the correlation better. In similar study, Ghosal
et al. [7] found that Lower Oesophageal Sphincter (LES) pressure
was reduced in the post- sclerotherapy group compared to the presclerotherapy group [7]. Their study was conducted using absolute
alcohol while most of our work has been done using sclerosants like
polidocanol. Their study concluded that oesophageal dysmotility is
commoner after sclerotherapy. However, there was no correlation
with histologic changes or any attempt to explain the changes if
any. There have been no other significant studies on the correlation
between histologic and manometric changes after repeated EST
since our paper was published and opened up the new field which
established a basis for the manometric changes observable after
repeated EST and the accompanying histologic changes. It is our
hope that further studies will be done with more patients to study
this in greater detail. This will help us to devise treatment protocols
for management of often severe oesophageal symptoms of chest pain,
oesophagitis, dysphagia and even stricture formation by treating the
cause rather than instituting symptomatic treatment.
References
- Sauerbruch T, Wong F. Treatment of Oesophageal Varices in Liver Cirrhosis. Digestion. 201:1-6.
- Iwakiri Y. Pathophysiology of portal hypertension. Clin Liver Dis. 2014;18(2):281-91.
- Miraglia R, Maruzzelli L, Luca A. Recanalization of occlusive transjugular intrahepatic portosystemic shunts inaccessible to the standard transvenous approach. Diagn Interv Radiol. 2013;19(1):61-5.
- Sharma P, Hagerstrand I, Sharma DK. Histologic and manometric studies on the oesophagus following endoscopic sclerotherapy. Dig Dis Sci. 2009;54(8):1713-9.
- Kitano S, Terblanche J, Kahn D, Bornman PC. Venous anatomy of the lower oesophagus in portal hypertension: practical implications. Br J Surg. 1986;73(7):525-31.
- Spence RA, Sloan JM, Johnston GW, Greenfield A. Oesophageal mucosal changes in patients with varices. Gut. 1983;24:1024-9.
- Ghoshal UC, Dhar K, Chaudhuri S, Pal BB, Pal AK, Banerjee PK. Esophageal motility changes after endoscopic intravariceal sclerotherapy with absolute alcohol. Dis Esophagus. 2000;13(2):148-51.
- Turco L, Villanueva C, Mura VL, Garcia-Pagan JC, Reiberger T, Genesca J, et al. A reduction in the hepatic venous pressure gradient (HVPG) prevents clinical outcomes in compensated and decompensated cirrhosis: a meta-analysis. J Hepatol. 2017;66(1):103-4.
- Tandon P, Abraldes JG, Berzigotti A, Garcia-Pagan JC, Bosch J. Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis. J Hepatol. 2010;53(2):273-82.
- Schierwagen R, Uschner FE, Magdaleno F, Klein S, Trebicka J. Rationale for the use of statins in liver disease. Am J Physiol Gastrointest Liver Physiol. 2017;312(5):407-12.